Morepen Laboratories Sets October 27 Q2 FY27 Results

Morepen Laboratories Ltd has informed the BSE that its Board of Directors will meet on October 27, 2026, to consider and approve financial results for the quarter and half year ended September 30, 2026. The meeting is scheduled to consider unaudited standalone and consolidated results for the second quarter of FY27. The disclosure was made on October 22, 2026. The result announcement follows a strong first-quarter performance reported in August. Investors will assess whether the company has sustained its revenue growth and improved profitability into the September quarter.

Board Meeting Scheduled for October 27

The board meeting intimation identifies October 27, 2026, as the date for considering the Q2 FY27 and first-half FY27 financial statements. The quarter under review covers July through September 2026. Morepen's previous earnings date was August 4, 2026, when it reported results for the quarter ended June 30, 2026. The company has stated that both standalone and consolidated numbers will be considered. The final Q2 figures were not included in the board-meeting announcement.

Trading Window Remains Closed

Morepen Laboratories has closed its trading window for designated persons and their immediate relatives from October 1, 2026. The window will remain closed until 48 hours after the financial results are declared. Based on the stated schedule, it extends through October 29, 2026. Such restrictions are intended to prevent trading while unpublished price-sensitive financial information is being considered by the board. The closure is linked specifically to the September-quarter and half-year result process.

June Quarter Sets the Reference Point

For the April-June 2026 quarter, Morepen Laboratories reported revenue of ₹570.13 crore and net profit of ₹56.40 crore. Revenue was up 34.07% year-on-year and 17.62% sequentially, according to the provided earnings data. Net profit increased 394.21% year-on-year and 258.85% quarter-on-quarter. The company also reported gross profit of ₹74 crore for the June quarter. Gross profit growth was listed at 389.96% year-on-year and 296.68% sequentially.

Key Financial Metrics From Q1 FY27

The June-quarter revenue compared with ₹425 crore in the corresponding quarter a year earlier, based on the provided results summary. The profit figure compared with ₹11 crore in the year-earlier quarter. These comparisons establish a higher base for evaluating the September-quarter disclosure. The upcoming results will provide the first reported view of Morepen's performance for the first half of FY27.

CDMO, API and Margin Trends in Focus

The company’s recent updates have highlighted CDMO activity, pharmaceutical margins and API expansion as relevant areas for investors. Morepen previously referred to the commercialisation of an ₹825 crore CDMO mandate. It also reported 31% API growth in its Q1 FY27 update. These operating details form part of the context around the company’s June-quarter revenue and profit improvement. However, the board-meeting announcement did not provide an outlook or updated operating guidance for Q2 FY27.

Half-Year Numbers Will Add Context

The October 27 meeting will cover both the September quarter and the six months ended September 30, 2026. Half-year figures will combine the June and September quarters, allowing investors to review performance across the first half of FY27. Morepen reported full-year FY26 net profit of ₹96 crore. Its Q1 FY27 net profit of ₹56.40 crore was therefore a material earnings figure relative to the prior full-year number. The half-year release will clarify the cumulative financial position after the second-quarter outcome is added.

Capital Return Data Provides Additional Context

Available data for Q1 FY27 showed a 12-month return on invested capital of 5.4%, against a cost of capital of 12%. For Q2 FY26, the reported return on capital employed was 7.2%, while return on invested capital was 8.8%. These measures offer a separate view from quarterly profit growth because they consider how effectively the business generates returns from invested capital. The supplied information does not provide comparable Q2 FY27 capital-return metrics ahead of the results. Any updated disclosures will be part of the company’s reported financial information.

What Investors Will Watch in the Results

Revenue continuity, gross-profit movement and net-profit performance will be central to the September-quarter assessment. Investors will also compare the Q2 numbers with the June-quarter revenue of ₹570.13 crore and net profit of ₹56.40 crore. Commentary on CDMO execution, API performance and pharmaceutical margins may provide operational context if the company includes it with the results. The announcement itself only confirms the meeting agenda and does not indicate the expected financial outcome. No Q2 FY27 revenue, profit or margin forecast has been disclosed in the provided information.

Next Confirmed Step

Morepen Laboratories’ board is scheduled to consider the unaudited standalone and consolidated Q2 FY27 and half-year FY27 results on October 27, 2026. The trading window is to remain closed until 48 hours after the results declaration. The final financial release will show whether the revenue and profit growth reported in the June quarter continued through September. Until then, the board-meeting notice remains a scheduling disclosure rather than a statement of Q2 performance.